For Financial Literacy Month, Tori Dunlap spoke with MarketWatch about the investing hurdles women and young people face right now
MarketWatch
Americans are ‘doom-buying’ coffee, olive oil and soap. What’s the one thing I should stockpile to avoid tariff price hikes?
Some purchases have echoes of the early days of the pandemic.
This is America’s ‘magic number’ for retirement – and it’s lower this year
Workers should replace 80% of their income for each year of retirement, new research suggests
Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and Zepbound maker Eli Lilly a lift.
I begged my adviser to sell amid the market turmoil. It took him days and I lost $20,000. Can I sue?
“If he had moved my money out of the market weeks ago, much of my loss could have been prevented.”
World to America: We’re not dependent on trade with you anymore
The U.S. is not the trade titan that Trump believes it is.
America’s generic-drug crisis can be fixed in two words: pharma tariffs
Strong U.S. production isn’t just good economic policy; it’s about national security and public health.
Investors are jittery about earnings — and that’s opening up big opportunities, say Goldman strategists
Looking at the demand for put over call options, fear remains at extreme levels despite the 90-day delay in most tariffs, say strategists led by John Marshall, head of derivatives research at Goldman Sachs.
‘The whole thing feels predatory’: My grandma, 97, pays $170 a month for a $10,000 life-insurance policy. Should we stop payments?
“After what quickly became a heated discussion, the agent advised me that canceling the policy would end any chance of a payout.”
Even after the selloff, U.S. stocks are still too pricey, says Citigroup, cutting them to neutral
Citigroup downgrades U.S. stocks to neutral, saying valuations are still too rich.